Global Health Valuation
Is GLH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GLH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GLH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GLH's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GLH?
Key metric: As GLH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is GLH's PS Ratio? | |
|---|---|
| PS Ratio | 0.9x |
| Sales | AU$8.66m |
| Market Cap | AU$7.98m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | -5.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GLH's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.4x | ||
VFX Visionflex Group | 1.7x | n/a | AU$11.7m |
ICR Intelicare Holdings | 18.9x | n/a | AU$5.4m |
ADR Adherium | 8.9x | 86.8% | AU$7.5m |
TRI TrivarX | 8.2x | n/a | AU$7.3m |
GLH Global Health | 0.9x | n/a | AU$8.0m |
Price-To-Sales vs Peers: GLH is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (9.4x).
Price to Sales Ratio vs Industry
How does GLH's PS Ratio compare vs other companies in the AU Healthcare Services Industry?
Price-To-Sales vs Industry: GLH is good value based on its Price-To-Sales Ratio (0.9x) compared to the Global Healthcare Services industry average (3x).
Price to Sales Ratio vs Fair Ratio
What is GLH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate GLH's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Doctor Care Anywhere Group
AU$23.5m
Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.
DOC
AU$0.064
7D
-4.5%
1Y
33.3%
Cogstate
AU$166.4m
A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.
CGS
AU$0.96
7D
-2.5%
1Y
-36.9%
CardieX
AU$30.9m
Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.
CDX
AU$0.10
7D
-22.2%
1Y
n/a